RT Journal Article
SR Electronic
T1 Effect of combination of interferon alpha-2b and interferon-gamma or interferon alpha-2b alone for elimination of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.29.20164251
DO 10.1101/2020.07.29.20164251
A1 Esquivel-Moynelo I Idelsis
A1 Pérez-Escribano J
A1 Duncan-Roberts Y
A1 Vazquez-Blonquist D Dania
A1 Bequet-Romero M
A1 Baez-Rodríguez L
A1 Castro-Ríos J
A1 Cobas Cervantes L
A1 Pagé-Calvet E
A1 Travieso-Pérez S
A1 Martinez-Suarez C
A1 Campa-Legra I Ivan
A1 Fernandez-Masso Julio Raul
A1 Camacho-Rodriguez H
A1 Díaz-Gálvez M
A1 Sin-Mayor A
A1 García-Sánchez M
A1 Martínez-Martín SM
A1 Alonso-Valdés M
A1 Hernandez-Bernal F
A1 Nodarse-Cuni H
A1 Bello-Garcia D
A1 Beato-Canfuk A
A1 Vizcaino M Tania
A1 Guillen-Nieto GE
A1 Lucila Muzio-Gonzalez VL Verena
A1 Bello-Rivero I
YR 2020
UL http://medrxiv.org/content/early/2020/08/04/2020.07.29.20164251.abstract
AB Objectives An IFN-α2b and IFN-γ combination has demonstrated favorable pharmacodynamics for genes underlying antiviral activity which might be involved in the defense of a host from a SARS-CoV-2 infection. Considering this synergy, we conducted a randomized controlled clinical trial for efficacy and safety evaluation of subcutaneous IFN - α2b and IFN-γ administration in patients positive for SARS-CoV-2.Methods We enrolled 19-82 years-old inpatients at the Military Central Hospital Luis Diaz Soto, Havana, Cuba. They were hospitalized after confirmed diagnosis for SARS-CoV-2 RNA by real-time reverse transcription polymerase chain reaction. Patients were randomly assigned in a 1:1 ratio to receive either, subcutaneous treatment with a co-lyophilized combination of 3.0 MIU IFN-α2b and 0.5 MIU IFN-γ (HeberFERON, CIGB, Havana, Cuba), twice a week for two weeks, or thrice a week intramuscular injection of 3.0 MIU IFN-α2b (Heberon® Alpha R, CIGB, Havana, Cuba). Additionally, all patients received lopinavir-ritonavir (200/50 mg every 12 h) and chloroquine (250 mg every 12 h, i.e.standard of care). The primary endpoints were, from the start of treatment, the time to elimination of viral RNA and the time to progression to severe COVID-19. The protocol was approved by the Ethics Committee on Clinical Investigation from the Hospital and the Center for the State Control of Medicines, Equipment and Medical Devices in Cuba. Informed consent was obtained from each participant (INSTITUTION PROTOCOL IG/IAG/CV/2001).Results A total of 79 patients with laboratory-confirmed SARS-CoV-2 infection, including symptomatic or asymptomatic conditions, fulfilled the inclusion criteria and underwent randomization. Thirty-three subjects were assigned to the HeberFERON group, and 33 to the Heberon Alpha R group. Sixty-three patients were analyzed for viral elimination, of these 78.6% in the HeberFERON group eliminated the virus after 4 days of treatment versus 40.6% of patients in the Heberon Alpha R groups (p=0.004). Time to reach the elimination of SARS-CoV-2, as measured by RT-PCR was 3.0 and 5.0 days for the HeberFERON and Heberon Alpha R groups, respectively. A significant improvement in the reduction of time for virus elimination was attributable to HeberFERON (p=0.0027, Log-rank test) with a Hazard Ratio of 3.2 and 95% CI of 1.529 to 6.948, as compared to the Heberon Alpha R treated group.Worsening of respiratory symptoms was detected in two (6.6%) and one (3.3%) patients in HeberFERON and IFN-α2b groups, respectively. However, none of the subjects transited to severe COVID-19 during the study or during the following clinical evaluation (21 more days).RT-PCR on day 14 after the start of the treatment was negative to SARS-CoV-2 in 100% and 91% of patients of the combination of IFNs and IFN-α2b, respectively. Elimination in HeberFERON treated patients was related to a significant increase in lymphocytes counts and also a significant reduction in CRP as early as 7 days after commencing the therapeutic schedule.All the patients in both cohorts recovered and had their laboratory parameters return to normal values by day 14 after treatment initiation. Adverse events were identified in 31.5% of patients, 28.5% in the control group, and 34.4% in the HeberFERON group, with the most frequent adverse event being headaches (17.4%).Conclusions In a cohort of 63 hospitalized patients between 19 to 82 years-old with positive SARS-CoV-2, HeberFERON significantly eliminated the virus on day 4 of treatment when compared to treatment with IFN-α2b alone. However, Heberon Alpha R alone also showed efficacy for the treatment of the viral infection. Both treatments were safe and positively impacted on the resolution of the symptoms. None of the patients developed severe COVID-19.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialRPCEC00000307Clinical Protocols https://www.researcsquare.com./article/rs-28958/v1 Funding StatementNo payment has been received for any actions conserning the trialAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:MINISTRY OF PUBLIC HEALTH Approval of the Review and Ethical Committee Province: Havana Hospital: Military Central Luis Diaz Soto, Hospital The members of the Review and Ethical Committee of the hospital institution before mentioned and signing certified that: The clinical trial protocol Evaluation of the effect and safety of HeberFERON vs Heberon Alpha in patients infected with corona virus SARS-CoV-2 (Study ESPERANZA/HOPE). Code: IG/IAG/CV/2001; Version: 01; Data: 01 April 2020 Whose sponsor is the Center for genetic Engineering and Biotechnology, has been evaluated by the Committee from ethical, scientific and methodological point of view. a.The protocol complies with the requisites of suitability with respect to rights, safety, and welfare of the patients. b.The protocol complies with the requisites of suitability with respect to study objectives, justification of risks, management of adverse events, the information present d to de investigators about the product characteristics, CRF c.Are true both, the informed consent and procedures to be obtained All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are not available by now